SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway
On December 16, 2024, Soligenix, Inc. (SNGX) announced it has opened patient enrollment for the confirmatory Phase 3 FLASH2 (Fluorescent Light...
230 Views
SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development
On October 2, 2024, two travelers in Hamburg, Germany were hospitalized due to displaying symptoms consistent with Marburg virus. The two...
264 Views
SNGX: Phase 3 Trial of HyBryte in CTCL to Initiate in 2H24
On August 9, 2024, Soligenix, Inc. (SNGX) announced financial results for the second quarter of 2024 and provided a business update. The company...
135 Views
SNGX: Phase 3 Trial of HyBryte in CTCL to Initiate in 2H24
On August 9, 2024, Soligenix, Inc. (SNGX) announced financial results for the second quarter of 2024 and provided a business update. The company...
150 Views
SNGX: Positive Interim Results for HyBryte in Investigator-Initiated Study in CTCL Raising Valuation to 35
On July 9, 2024, Soligenix, Inc. (SNGX) announced positive interim results for HyBryte in an open-label, investigator-initiated study in patients...
190 Views